Takeuchi Koji, Miyazawa Tohru, Matsumoto Masahiro, Hayashi Yujiro
Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Misasagi, Yamashina, Kyoto, Japan.
Digestion. 2003;68(2-3):71-9. doi: 10.1159/000074518. Epub 2003 Oct 24.
BACKGROUND/AIM: 2-deoxy-D-glucose (2DG), despite causing gastric hypermotility via vagal stimulation, does not by itself induce damage in the stomach but produces gross lesions under prostaglandin (PG) deficiency induced by non-ulcerogenic dose of indomethacin. In this study, we examined the roles PG and cyclo-oxygenase (COX) isozymes play in the gastric ulcerogenic effect of 2DG in the rat stomach under PG deficiency caused by indomethacin.
The animals were given 2DG i.v. (200 mg/kg as a bolus injection followed by an infusion at 100 mg/kg), and the mucosa was examined for lesions 8 h later. SC-560 or/and rofecoxib was given p.o. 1 h before 2DG treatment.
2DG alone caused slight damage in the stomach despite causing acid hypersecretion and hypermotility. Neither SC-560 nor rofecoxib alone caused any damage in the stomach, yet these agents significantly aggravated 2DG-induced gastric lesions; the severity of damage was much greater when SC-560 was given together with 2DG. SC-560, but not rofecoxib, enhanced both acid secretion and gastric motility in response to 2DG, with a decrease in mucosal PGE2 content. Expression of COX-2 was up-regulated in the stomach as early as 2 h after 2DG treatment, and the PGE2 content was increased when determined 6 h later, in a COX-2-dependent/rofecoxib-sensitive manner. Both the expression of COX-2 and gastric hypermotility during 2DG treatment were inhibited by prior administration of atropine but not omeprazole, although 2DG-induced gastric lesions were prevented by both agents.
These results suggest that potentiation by indomethacin of 2DG-induced gastric lesions is related to inhibition of both COX-1 and COX-2, and that 2DG up-regulates COX-2 in the gastric mucosa, the event occurring in association with gastric hypermotility and contributing to suppression of later extension of the damage.
背景/目的:2-脱氧-D-葡萄糖(2DG)尽管通过迷走神经刺激引起胃动力亢进,但其本身不会导致胃损伤,但在非致溃疡剂量的吲哚美辛诱导的前列腺素(PG)缺乏情况下会产生严重病变。在本研究中,我们研究了PG和环氧化酶(COX)同工酶在吲哚美辛引起的PG缺乏情况下2DG对大鼠胃的致溃疡作用中所起的作用。
给动物静脉注射2DG(先静脉推注200mg/kg,随后以100mg/kg持续输注),8小时后检查胃黏膜的病变情况。在2DG治疗前1小时口服给予SC-560或/和罗非昔布。
单独使用2DG尽管会引起胃酸分泌过多和胃动力亢进,但仅造成胃的轻微损伤。单独使用SC-560或罗非昔布均未引起胃损伤,但这些药物显著加重了2DG诱导的胃损伤;当SC-560与2DG联合使用时,损伤的严重程度更大。SC-560而非罗非昔布增强了2DG引起的胃酸分泌和胃动力,同时黏膜PGE2含量降低。2DG治疗后2小时内,胃中COX-2的表达上调,6小时后测定时,PGE2含量以COX-2依赖性/罗非昔布敏感的方式增加。2DG治疗期间COX-2的表达和胃动力亢进均被预先给予的阿托品抑制,但未被奥美拉唑抑制,尽管两种药物均能预防2DG诱导的胃损伤。
这些结果表明,吲哚美辛增强2DG诱导的胃损伤与COX-1和COX-2的抑制有关,并且2DG上调胃黏膜中的COX-2,这一事件与胃动力亢进相关并有助于抑制损伤的后期扩展。